Gliosarcoma - Pipeline Review, H2 2017

  • ID: 4432182
  • Report
  • 215 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Agenus Inc
  • Bristol-Myers Squibb Co
  • Celgene Corp
  • ERC Belgium SA
  • Ipsen SA
  • MORE
Gliosarcoma - Pipeline Review, H2 2017

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Gliosarcoma - Pipeline Review, H2 2017, provides an overview of the Gliosarcoma (Oncology) pipeline landscape.

Gliosarcoma is a type of brain tumor that originates from glial cells. The tumor grows rapidly and symptom will vary depending on the exact location and size of the tumor. Most likely they may be headache, vomiting, cognitive problems, and drowsiness. Treatment of brain tumors depends upon the type and staging of the tumor, its size and position in the brain, as well as the age and other health problems of patient.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Gliosarcoma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Gliosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gliosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gliosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 1, 14 and 12 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Gliosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gliosarcoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Gliosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gliosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gliosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gliosarcoma (Oncology)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gliosarcoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gliosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Agenus Inc
  • Bristol-Myers Squibb Co
  • Celgene Corp
  • ERC Belgium SA
  • Ipsen SA
  • MORE
Introduction

Gliosarcoma - Overview

Gliosarcoma - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Gliosarcoma - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Gliosarcoma - Companies Involved in Therapeutics Development

AbbVie Inc

Agenus Inc

Bristol-Myers Squibb Co

Celgene Corp

DelMar Pharmaceuticals Inc

ERC Belgium SA

Ipsen SA

Kite Pharma Inc

Merck & Co Inc

Millennium Pharmaceuticals Inc

NewLink Genetics Corp

Northwest Biotherapeutics Inc

Novartis AG

Nuo Therapeutics Inc

Gliosarcoma - Drug Profiles

ALD-451 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alisertib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

avadomide hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target CD3 and EGFR for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target EGFR vIII for Glioblastoma Multiforme and Gliosarcoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dasatinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DCVax-L - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

depatuxizumab mafodotin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dianhydrogalactitol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DNX-2401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ERC-1671 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

flucytosine + TBio-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

G-200 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

indoximod - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

irinotecan hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

irinotecan hydrochloride + TBio-02 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lonafarnib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-032 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

marizomib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

p28 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pazopanib hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pembrolizumab - Drug Profile

R&D Progress

relatlimab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RRX-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sapanisertib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SGT-53 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TG-02 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

urelumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gliosarcoma - Dormant Projects

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Gliosarcoma, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Gliosarcoma - Pipeline by AbbVie Inc, H2 2017

Gliosarcoma - Pipeline by Agenus Inc, H2 2017

Gliosarcoma - Pipeline by Bristol-Myers Squibb Co, H2 2017

Gliosarcoma - Pipeline by Celgene Corp, H2 2017

Gliosarcoma - Pipeline by DelMar Pharmaceuticals Inc, H2 2017

Gliosarcoma - Pipeline by ERC Belgium SA, H2 2017

Gliosarcoma - Pipeline by Ipsen SA, H2 2017

Gliosarcoma - Pipeline by Kite Pharma Inc, H2 2017

Gliosarcoma - Pipeline by Merck & Co Inc, H2 2017

Gliosarcoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2017

Gliosarcoma - Pipeline by NewLink Genetics Corp, H2 2017

Gliosarcoma - Pipeline by Northwest Biotherapeutics Inc, H2 2017

Gliosarcoma - Pipeline by Novartis AG, H2 2017

Gliosarcoma - Pipeline by Nuo Therapeutics Inc, H2 2017

Gliosarcoma - Dormant Projects, H2 2017

List of Figures

Number of Products under Development for Gliosarcoma, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AbbVie Inc
  • Agenus Inc
  • Bristol-Myers Squibb Co
  • Celgene Corp
  • DelMar Pharmaceuticals Inc
  • ERC Belgium SA
  • Ipsen SA
  • Kite Pharma Inc
  • Merck & Co Inc
  • Millennium Pharmaceuticals Inc
  • NewLink Genetics Corp
  • Northwest Biotherapeutics Inc
  • Novartis AG
  • Nuo Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll